The epidemiological significance of Anti-VEGF therapy lies in its impact on public health. Conditions like AMD and diabetic retinopathy are major causes of blindness worldwide. By effectively managing these conditions, Anti-VEGF therapy can significantly reduce the burden of vision impairment, thereby improving quality of life and reducing healthcare costs.
